Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Heterogeneity of treatment effect
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Heterogeneity of treatment effect

1 evidence topic · 1 source

Heterogeneity of treatment resistance

“This study demonstrates extensive intra- and inter-lesional heterogeneity of resistance mutations and gene amplification in patients with clinically progressing GIST.” (opens the source at this quote in a new tab)